
## Pierre-Emmanuel Rautou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2187381/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Liver surface nodularity on non-contrast MRI identifies advanced fibrosis in patients with NAFLD. European Radiology, 2022, 32, 1781-1791.	4.5	8
2	Multicenter study on recent portal venous system thrombosis associated with cytomegalovirus disease. Journal of Hepatology, 2022, 76, 115-122.	3.7	6
3	MR imaging features and long-term evolution of benign focal liver lesions in Budd-Chiari syndrome and Fontan-associated liver disease. Diagnostic and Interventional Imaging, 2022, 103, 111-120.	3.2	6
4	Role of Imaging in the Study of Vascular Disorders of the Liver. , 2022, , 15-33.		2
5	Pregnancy in Vascular Liver Disease. , 2022, , 237-248.		0
6	Role of Liver Biopsy in the Study of Vascular Disorders of the Liver. , 2022, , 3-13.		0
7	Performance of non-invasive biomarkers compared with invasive methods for risk prediction of posthepatectomy liver failure in hepatocellular carcinoma. British Journal of Surgery, 2022, 109, 455-463.	0.3	7
8	Contrastâ€enhanced CT and liver surface nodularity for the diagnosis of portoâ€sinusoidal vascular disorder: A caseâ€control study. Hepatology, 2022, 76, 418-428.	7.3	11
9	EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. Journal of Hepatology, 2022, 76, 1151-1184.	3.7	112
10	Reply. Hepatology, 2022, 76, E55-E56.	7.3	0
11	Imaging-guided interventions modulating portal venous flow: evidence and controversies. JHEP Reports, 2022, , 100484.	4.9	1
12	Impact of SARS-CoV-2 Pandemic on Vascular Liver Diseases. Clinical Gastroenterology and Hepatology, 2022, 20, 1525-1533.e5.	4.4	9
13	Portal vein recanalisation alone to treat severe portal hypertension in non-cirrhotic patients with chronic extrahepatic portal vein obstruction. JHEP Reports, 2022, 4, 100511.	4.9	10
14	Elastography improves accuracy of early hepato-biliary complications diagnosis after allogeneic stem cell transplantation. Haematologica, 2021, 106, 2374-2383.	3.5	14
15	Benefits of molecular profiling with next-generation sequencing for the diagnosis and prognosis of myeloproliferative neoplasms in splanchnic vein thrombosis. Journal of Hepatology, 2021, 74, 251-252.	3.7	5
16	Computed Tomography-Derived Liver Surface Nodularity and Sarcopenia as Prognostic Factors in Patients with Resectable Metabolic Syndrome-Related Hepatocellular Carcinoma. Annals of Surgical Oncology, 2021, 28, 405-416.	1.5	10
17	Liver Stiffness by Transient Elastography to Detect Porto‣inusoidal Vascular Liver Disease With Portal Hypertension. Hepatology, 2021, 74, 364-378.	7.3	40
18	Patients with NAFLD do not have severe portal hypertension in the absence of cirrhosis. Journal of Hepatology, 2021, 74, 1269-1270.	3.7	7

#	Article	IF	CITATIONS
19	Venous thrombosis and predictors of relapse in eosinophil-related diseases. Scientific Reports, 2021, 11, 6388.	3.3	18
20	Endothelial dysfunction markers predict short-term mortality in patients with severe alcoholic hepatitis. Hepatology International, 2021, 15, 1006-1017.	4.2	6
21	REPLY:. Hepatology, 2021, 74, 2317-2318.	7.3	0
22	REPLY:. Hepatology, 2021, 74, 2911-2912.	7.3	0
23	Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study. Journal of Hepatology, 2021, 75, 1026-1033.	3.7	59
24	NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF VASCULAR LIVER DISEASES. Clinics and Research in Hepatology and Gastroenterology, 2021, 46, 101764.	1.5	1
25	Role of extracellular vesicles in liver diseases and their therapeutic potential. Advanced Drug Delivery Reviews, 2021, 175, 113816.	13.7	37
26	Systemic inflammation as a risk factor for portal vein thrombosis in cirrhosis: a prospective longitudinal study. European Journal of Gastroenterology and Hepatology, 2021, 33, e108-e113.	1.6	16
27	Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation. Journal of Hepatology, 2020, 72, 463-471.	3.7	38
28	Prevalence, features and predictive factors of liver nodules in Fontan surgery patients: The VALDIG Fonliver prospective cohort. Journal of Hepatology, 2020, 72, 702-710.	3.7	45
29	A defect in endothelial autophagy occurs in patients with non-alcoholic steatohepatitis and promotes inflammation and fibrosis. Journal of Hepatology, 2020, 72, 528-538.	3.7	113
30	Quantification of hepatic steatosis with ultrasound: promising role of attenuation imaging coefficient in a biopsy-proven cohort. European Radiology, 2020, 30, 2293-2301.	4.5	65
31	Performance of liver surface nodularity quantification for the diagnosis of portal hypertension in patients with cirrhosis: comparison between MRI with hepatobiliary phase sequences and CT. Abdominal Radiology, 2020, 45, 365-372.	2.1	16
32	Extracellular vesicles as biomarkers in liver diseases: A clinician's point of view. Journal of Hepatology, 2020, 73, 1507-1525.	3.7	105
33	Similar performance of liver stiffness measurement and liver surface nodularity for the detection of portal hypertension in patients with hepatocellular carcinoma. JHEP Reports, 2020, 2, 100147.	4.9	15
34	Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses. Blood Advances, 2020, 4, 3708-3715.	5.2	31
35	Interaction between the autophagy protein Beclin 1 and Na+,K+-ATPase during starvation, exercise, and ischemia. JCI Insight, 2020, 5, .	5.0	37
36	No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease. Journal of Hepatology, 2020, 73, 717-718.	3.7	42

#	Article	IF	CITATIONS
37	Hepatobiliary MR contrast agents are useful to diagnose hepatocellular carcinoma in patients with Budd-Chiari syndrome. JHEP Reports, 2020, 2, 100097.	4.9	11
38	2D shear wave liver elastography by Aixplorer to detect portal hypertension in cirrhosis: An individual patient data metaâ€analysis. Liver International, 2020, 40, 1435-1446.	3.9	35
39	Porto-sinusoidal vascular disease. Vascular liver diseases: Position papers from the francophone network for vascular liver diseases, the French Association for the Study of the Liver (AFEF), and ERN-rare liver. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 447-451.	1.5	5
40	Characterization of Blood Immune Cells in Patients With Decompensated Cirrhosis Including ACLF. Frontiers in Immunology, 2020, 11, 619039.	4.8	39
41	Ischemic cholangiopathy: An update. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 486-490.	1.5	7
42	Microcirculatory changes in the liver of patients with refractory ascites and their relationship with diabetes and alcohol. European Journal of Gastroenterology and Hepatology, 2020, Publish Ahead of Print, .	1.6	2
43	Erythrocyte-derived microvesicles induce arterial spasms in JAK2V617F myeloproliferative neoplasm. Journal of Clinical Investigation, 2020, 130, 2630-2643.	8.2	42
44	Liver Disease; Hemostasis and Coagulation Disorders. , 2020, , 418-428.		0
45	Angioplasty with stenting for Budd-Chiari syndrome. The Lancet Gastroenterology and Hepatology, 2019, 4, 657-659.	8.1	3
46	Autophagy in liver diseases: Time for translation?. Journal of Hepatology, 2019, 70, 985-998.	3.7	252
47	Nonselective betaâ€blockers and the risk of portal vein thrombosis in patients with cirrhosis: results of a prospective longitudinal study. Alimentary Pharmacology and Therapeutics, 2019, 49, 582-588.	3.7	48
48	Comparison of endothelial promoter efficiency and specificity in mice reveals a subset of Pdgfbâ€positive hematopoietic cells. Journal of Thrombosis and Haemostasis, 2019, 17, 827-840.	3.8	24
49	Abdominal Surgery in Patients With Idiopathic Noncirrhotic Portal Hypertension: A Multicenter Retrospective Study. Hepatology, 2019, 70, 911-924.	7.3	11
50	Understanding the Similarities and Differences between Hepatic and Pulmonary Veno-Occlusive Disease. American Journal of Pathology, 2019, 189, 1159-1175.	3.8	19
51	Porto-sinusoidal vascular disease: proposal and description of a novel entity. The Lancet Gastroenterology and Hepatology, 2019, 4, 399-411.	8.1	149
52	Short―and Longâ€īerm Outcomes of Liver Resection for Intrahepatic Cholangiocarcinoma Associated with the Metabolic Syndrome. World Journal of Surgery, 2019, 43, 2048-2060.	1.6	17
53	Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease. Journal of Hepatology, 2019, 70, 1278-1291.	3.7	186
54	Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis. Journal of Hepatology, 2019, 71, 175-199.	3.7	80

#	Article	IF	CITATIONS
55	Reply to: ''Splenic artery aneurysms, portal hypertension and pregnancy― Journal of Hepatology, 2019, 70, 1026-1027.	3.7	2
56	Low specificity of washout to diagnose hepatocellular carcinoma in nodules showing arterial hyperenhancement in patients with Budd-Chiari syndrome. Journal of Hepatology, 2019, 70, 1123-1132.	3.7	37
57	Evidence for an Association Between Intrahepatic Vascular Changes and the Development of Hepatopulmonary Syndrome. Chest, 2019, 155, 123-136.	0.8	21
58	Primary cilia sensitize endothelial cells to BMP and prevent excessive vascular regression. Journal of Cell Biology, 2018, 217, 1651-1665.	5.2	84
59	Endothelial Autophagy Does Not Influence Venous Thrombosis in Mice. Thrombosis and Haemostasis, 2018, 118, 1113-1115.	3.4	3
60	Benign and malignant hepatocellular lesions in patients with vascular liver diseases. Abdominal Radiology, 2018, 43, 1968-1977.	2.1	44
61	Endothelial JAK2 does not enhance liver lesions in mice with Budd-Chiari syndrome. Journal of Hepatology, 2018, 68, 1086-1087.	3.7	3
62	Diagnosis of Budd–Chiari syndrome. Abdominal Radiology, 2018, 43, 1896-1907.	2.1	35
63	Nonâ€invasive evaluation of portal hypertension using shearâ€wave elastography: analysis of two algorithms combining liver and spleen stiffness in 191 patients with cirrhosis. Alimentary Pharmacology and Therapeutics, 2018, 47, 621-630.	3.7	46
64	Bleeding risk of variceal band ligation in extrahepatic portal vein obstruction is not increased by oral anticoagulation. European Journal of Gastroenterology and Hepatology, 2018, 30, 563-568.	1.6	17
65	Hepatocyte microvesicle levels improve prediction of mortality in patients with cirrhosis. Hepatology, 2018, 68, 1508-1518.	7.3	33
66	NADPH oxidase depletion in neutrophils from patients with cirrhosis and restoration via toll-like receptor 7/8 activation. Gut, 2018, 67, 1505-1516.	12.1	29
67	Endothelial autophagic flux hampers atherosclerotic lesion development. Autophagy, 2018, 14, 173-175.	9.1	24
68	Ultraâ€short bowel is an independent risk factor for liver fibrosis in adults with home parenteral nutrition. Liver International, 2018, 38, 174-182.	3.9	30
69	Ultrasonic fat fraction quantification using <i>in vivo</i> adaptive sound speed estimation. Physics in Medicine and Biology, 2018, 63, 215013.	3.0	38
70	Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis. Gastroenterology, 2018, 155, 1816-1827.e9.	1.3	113
71	Quantification of Liver Surface Nodularity at CT: Utility for Detection of Portal Hypertension. Radiology, 2018, 289, 698-707.	7.3	45
72	Cirrhosis regression: extrahepatic angiogenesis and liver hyperarterialization persist. Clinical Science, 2018, 132, 1341-1343.	4.3	4

#	Article	IF	CITATIONS
73	Pregnancy in idiopathic non-cirrhotic portal hypertension: A multicentric study on maternal and fetal management and outcome. Journal of Hepatology, 2018, 69, 1242-1249.	3.7	26
74	Mucosal-associated invariant T cells are a profibrogenic immune cell population in the liver. Nature Communications, 2018, 9, 2146.	12.8	152
75	Type I interferon signaling in systemic immune cells from patients with alcoholic cirrhosis and its association with outcome. Journal of Hepatology, 2017, 66, 930-941.	3.7	26
76	Extracellular vesicles in coronary artery disease. Nature Reviews Cardiology, 2017, 14, 259-272.	13.7	392
77	A prospective study of the utility of plasma biomarkers to diagnose alcoholic hepatitis. Hepatology, 2017, 66, 555-563.	7.3	91
78	Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study. Journal of Hepatology, 2017, 67, 501-507.	3.7	50
79	lloprost Use in Patients with Persistent Intestinal Ischemia Unsuitable for Revascularization. Annals of Vascular Surgery, 2017, 42, 128-135.	0.9	6
80	Autophagy is required for endothelial cell alignment and atheroprotection under physiological blood flow. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E8675-E8684.	7.1	156
81	Quantitative Imaging in Diffuse Liver Diseases. Seminars in Liver Disease, 2017, 37, 243-258.	3.6	11
82	Pre-therapy liver transcriptome landscape in Indian and French patients with severe alcoholic hepatitis and steroid responsiveness. Scientific Reports, 2017, 7, 6816.	3.3	16
83	Idiopathic Non-cirrhotic Portal Hypertension and Close Entities: a Need for Clarifying Terminology. Current Hepatology Reports, 2017, 16, 237-240.	0.9	0
84	Reply to: "Calreticulin mutations and their importance in Budd-Chiari syndrome― Journal of Hepatology, 2017, 67, 1112-1113.	3.7	0
85	Long-term Outcome and Analysis of Dysfunction of Transjugular Intrahepatic Portosystemic Shunt Placement in Chronic Primary Budd-Chiari Syndrome. Radiology, 2017, 283, 280-292.	7.3	54
86	Liver sinusoidal endothelial cells: Physiology and role in liver diseases. Journal of Hepatology, 2017, 66, 212-227.	3.7	639
87	Role of the transjugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension. Hepatology, 2016, 64, 224-231.	7.3	69
88	Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis. Hepatology, 2016, 63, 1640-1650.	7.3	73
89	Arterial hypertension as an uninvited player in hepatic stiffness?. American Journal of Physiology - Renal Physiology, 2016, 311, G942-G944.	3.4	3
90	LPS-TLR4 Pathway Mediates Ductular Cell Expansion in Alcoholic Hepatitis. Scientific Reports, 2016, 6, 35610.	3.3	25

#	Article	IF	CITATIONS
91	Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver International, 2016, 36, 936-948.	3.9	139
92	Idiopathic nonâ€cirrhotic portal hypertension: the tip of the obliterative portal venopathies iceberg?. Liver International, 2016, 36, 325-327.	3.9	11
93	Lack of clinical or haemodynamic rebound after abrupt interruption of betaâ€blockers in patients with cirrhosis. Alimentary Pharmacology and Therapeutics, 2016, 43, 966-973.	3.7	11
94	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
95	Hepatocyte tissue factor contributes to the hypercoagulable state in a mouse model of chronic liver injury. Journal of Hepatology, 2016, 64, 53-59.	3.7	36
96	Acute extrahepatic infectious or inflammatory diseases are a cause of transient mosaic pattern on CT and MR imaging related to sinusoidal dilatation of the liver. European Radiology, 2016, 26, 3094-3101.	4.5	19
97	Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression. Gut, 2016, 65, 1882-1894.	12.1	140
98	The significance of nonobstructive sinusoidal dilatation of the liver: Impaired portal perfusion or inflammatory reaction syndrome. Hepatology, 2015, 62, 956-963.	7.3	54
99	Autosis occurs in the liver of patients with severe anorexia nervosa. Hepatology, 2015, 62, 657-658.	7.3	35
100	Portal myofibroblasts promote vascular remodeling underlying cirrhosis formation through the release of microparticles. Hepatology, 2015, 61, 1041-1055.	7.3	102
101	Pregnancy and Vascular Liver Disease. Journal of Clinical and Experimental Hepatology, 2015, 5, 41-50.	0.9	42
102	Interplay of Inflammation and Endothelial Dysfunction in Bone Marrow Transplantation: Focus on Hepatic Veno-Occlusive Disease. Seminars in Thrombosis and Hemostasis, 2015, 41, 629-643.	2.7	48
103	Resolution of liver fibrosis requires myeloid cell–driven sinusoidal angiogenesis. Hepatology, 2015, 61, 2042-2055.	7.3	79
104	Prospective Comparison of Spleen and Liver Stiffness by Using Shear-Wave and Transient Elastography for Detection of Portal Hypertension in Cirrhosis. Radiology, 2015, 275, 589-598.	7.3	190
105	Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: Results of a longitudinal study. Hepatology, 2015, 61, 660-667.	7.3	364
106	Liver Autophagy in Anorexia Nervosa and Acute Liver Injury. BioMed Research International, 2014, 2014, 1-10.	1.9	44
107	Circulating microparticle tissue factor activity Is increased in patients with cirrhosis. Hepatology, 2014, 60, 1793-1795.	7.3	31
108	Managing periprocedural thrombocytopenia in cirrhosis: Aiming for a safety window. Journal of Hepatology, 2014, 61, 1199-1201.	3.7	2

#	Article	IF	CITATIONS
109	Budd-Chiari syndrome. Clinical Liver Disease, 2014, 3, 133-136.	2.1	2
110	Benign and malignant hepatocellular lesions in patients with vascular liver disease. Clinical Liver Disease, 2014, 3, 122-125.	2.1	3
111	The emerging roles of microvesicles in liver diseases. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 350-361.	17.8	158
112	Assessment of portal hypertension and high-risk oesophageal varices with liver and spleen three-dimensional multifrequency MR elastography in liver cirrhosis. European Radiology, 2014, 24, 1394-402.	4.5	103
113	Inhibition of MicroRNA-92a Prevents Endothelial Dysfunction and Atherosclerosis in Mice. Circulation Research, 2014, 114, 434-443.	4.5	317
114	Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology, 2014, 60, 823-831.	7.3	135
115	Type 2 diabetes mellitus as a risk factor for intestinal resection in patients with superior mesenteric vein thrombosis. Liver International, 2014, 34, 1314-1321.	3.9	48
116	Editorial: G-CSF Therapy for Severe Alcoholic Hepatitis: Targeting Liver Regeneration or Neutrophil Function?. American Journal of Gastroenterology, 2014, 109, 1424-1426.	0.4	29
117	Gene- and exon-expression profiling reveals an extensive LPS-induced response in immune cells in patients with cirrhosis. Journal of Hepatology, 2013, 58, 936-948.	3.7	66
118	Circulating platelet derived microparticles are not increased in patients with cirrhosis. Journal of Hepatology, 2013, 59, 912.	3.7	7
119	Microvesicles as risk markers for venous thrombosis. Expert Review of Hematology, 2013, 6, 91-101.	2.2	51
120	Management of hepatic vascular diseases. Journal of Hepatology, 2012, 56, S25-S38.	3.7	167
121	Endothelial Cell–derived Microparticles Loaded with Iron Oxide Nanoparticles: Feasibility of MR Imaging Monitoring in Mice. Radiology, 2012, 263, 169-178.	7.3	38
122	Severe hyponatremia is a better predictor of mortality than MELDNa in patients with cirrhosis and refractory ascites. Journal of Hepatology, 2012, 57, 274-280.	3.7	67
123	Abnormal Plasma Microparticles Impair Vasoconstrictor Responses in Patients With Cirrhosis. Gastroenterology, 2012, 143, 166-176.e6.	1.3	105
124	Endothelial progenitor cells in cirrhosis: The more, the merrier?. Journal of Hepatology, 2012, 57, 1163-1165.	3.7	8
125	Del-etion of Microvesicles From the Circulation. Circulation, 2012, 125, 1601-1604.	1.6	22
126	Changes in Autophagic Response in Patients with Chronic Hepatitis C Virus Infection. American Journal of Pathology, 2011, 178, 2708-2715.	3.8	58

#	Article	IF	CITATIONS
127	Predictors of tumor response after preoperative chemoradiotherapy for rectal adenocarcinomas. Human Pathology, 2011, 42, 1702-1709.	2.0	28
128	Bleeding in patients with Budd–Chiari syndrome. Journal of Hepatology, 2011, 54, 56-63.	3.7	61
129	Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: A cross-over study. Journal of Hepatology, 2011, 55, 794-799.	3.7	177
130	Microparticles, Vascular Function, and Atherothrombosis. Circulation Research, 2011, 109, 593-606.	4.5	331
131	Microparticles From Human Atherosclerotic Plaques Promote Endothelial ICAM-1–Dependent Monocyte Adhesion and Transendothelial Migration. Circulation Research, 2011, 108, 335-343.	4.5	221
132	Syndrome deÂBudd-Chiari primitif. Sang Thrombose Vaisseaux, 2010, 22, 201-208.	0.1	1
133	Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology, 2010, 52, 1017-1022.	7.3	452
134	The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study. Liver International, 2010, 30, 725-732.	3.9	149
135	Magnetic tagging of cell-derived microparticles: new prospects for imaging and manipulation of these mediators of biological information. Nanomedicine, 2010, 5, 727-738.	3.3	18
136	Microparticles: Key Protagonists in Cardiovascular Disorders. Seminars in Thrombosis and Hemostasis, 2010, 36, 907-916.	2.7	127
137	Dysphagia in a Patient With Recurrent Bilateral Eyelid Ptosis. Gastroenterology, 2010, 139, 1835-2226.	1.3	0
138	Autophagy in liver diseases. Journal of Hepatology, 2010, 53, 1123-1134.	3.7	351
139	Prognostic Indices for Budd–Chiari Syndrome: Valid for Clinical Studies but Insufficient for Individual Management. American Journal of Gastroenterology, 2009, 104, 1140-1146.	0.4	65
140	Pregnancy in women with known and treated Budd–Chiari syndrome: Maternal and fetal outcomes. Journal of Hepatology, 2009, 51, 47-54.	3.7	85
141	Comparative protein expression profiles of hilar and peripheral hepatic cholangiocarcinomas. Journal of Hepatology, 2009, 51, 93-101.	3.7	83
142	Levels and Initial Course of Serum Alanine Aminotransferase Can Predict Outcome of Patients With Budd–Chiari Syndrome. Clinical Gastroenterology and Hepatology, 2009, 7, 1230-1235.	4.4	39
143	Acute Liver Cell Damage in Patients With Anorexia Nervosa: A Possible Role of Starvation-Induced Hepatocyte Autophagy. Gastroenterology, 2008, 135, 840-848.e3.	1.3	165
144	CD40 Ligand+ Microparticles From Human Atherosclerotic Plaques Stimulate Endothelial Proliferation and Angiogenesis. Journal of the American College of Cardiology, 2008, 52, 1302-1311.	2.8	176

#	Article	IF	CITATIONS
145	Morphologic Changes in Branch Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Midterm Follow-Up Study. Clinical Gastroenterology and Hepatology, 2008, 6, 807-814.	4.4	117
146	Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion after pegylated interferon-??2b plus ribavirin treatment in a patient with hepatitis B and C coinfection. European Journal of Gastroenterology and Hepatology, 2006, 18, 1019-1022.	1.6	16